- Home
- BTAI vs ALGS Comparison
BTAI vs ALGS Comparison
Compare BTAI & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- ALGS
- Stock Information
- Founded
- BTAI 2017
- ALGS 2018
- Country
- BTAI United States
- ALGS United States
- Employees
- BTAI N/A
- ALGS N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- ALGS Health Care
- Exchange
- BTAI Nasdaq
- ALGS Nasdaq
- Market Cap
- BTAI 52.7M
- ALGS 53.0M
- IPO Year
- BTAI 2018
- ALGS 2020
- Fundamental
- Price
- BTAI $2.66
- ALGS $9.93
- Analyst Decision
- BTAI Buy
- ALGS Strong Buy
- Analyst Count
- BTAI 5
- ALGS 2
- Target Price
- BTAI $32.80
- ALGS $60.00
- AVG Volume (30 Days)
- BTAI 1.5M
- ALGS 71.0K
- Earning Date
- BTAI 11-13-2025
- ALGS 11-05-2025
- Dividend Yield
- BTAI N/A
- ALGS N/A
- EPS Growth
- BTAI N/A
- ALGS N/A
- EPS
- BTAI N/A
- ALGS N/A
- Revenue
- BTAI $868,000.00
- ALGS $3,174,000.00
- Revenue This Year
- BTAI N/A
- ALGS N/A
- Revenue Next Year
- BTAI $614.78
- ALGS N/A
- P/E Ratio
- BTAI N/A
- ALGS N/A
- Revenue Growth
- BTAI N/A
- ALGS N/A
- 52 Week Low
- BTAI $1.17
- ALGS $3.76
- 52 Week High
- BTAI $13.28
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- BTAI 38.51
- ALGS 50.93
- Support Level
- BTAI $2.42
- ALGS $9.66
- Resistance Level
- BTAI $2.70
- ALGS $10.64
- Average True Range (ATR)
- BTAI 0.19
- ALGS 0.70
- MACD
- BTAI 0.00
- ALGS -0.02
- Stochastic Oscillator
- BTAI 12.17
- ALGS 42.32
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.